Showing results (291-300 of 319) with videos related to

Sort By:
Pageof 32
Molecular Cancer Therapeutics|November 5, 2016
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of LapatinibMichael F Press, Catherine E Ellis, Robert C Gagnon, et al.
Cancer Research and Treatment|November 18, 2022
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, et al.
Gut|October 8, 2020
Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk populationJimmy Bok Yan So, Ritika Kapoor, Feng Zhu, et al.
Oncotarget|February 10, 2016
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimusSun Min Lim, Hyung Soon Park, Sangwoo Kim, et al.
Oncotarget|June 23, 2016
Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapyHyo Song Kim, Su-Jin Shin, Seung-Hoon Beom, et al.
JAMA Oncology|September 23, 2016
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh ScoreAndrew X Zhu, Ari David Baron, Peter Malfertheiner, et al.
The Lancet. Oncology|January 14, 2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialYoon-Koo Kang, Li-Tzong Chen, Min-Hee Ryu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|December 22, 2019
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update dataLi-Tzong Chen, Taroh Satoh, Min-Hee Ryu, et al.
Nature Medicine|February 12, 2013
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerJeong Heo, Tony Reid, Leyo Ruo, et al.
JCI Insight|October 5, 2016
PRL3-zumab, a first-in-class humanized antibody for cancer therapyMin Thura, Abdul Qader Omer Al-Aidaroos, Wei Peng Yong, et al.
Pageof 32